Valneva Shares Slide to €2.39, Approaching Critical Support at €2.26
The stock of the vaccine-specialized lab continues to decline this Wednesday at midday. Valneva is down 1.96% at €2.3980, while the SBF 120 index is up 0.56% during the session. The biotech is trading very close to its technical support set at €2.26.
The Stock Continues Its Slide Following a Reorganization Plan Announced Last Week
Valneva is down 1.96% at €2.3980, ranking among the largest declines in the SBF 120, while the broader index gains 0.56%. The weekly loss reaches 5.22%, and the stock has fallen nearly 48% over three months. This movement follows the publication of the first quarter accounts on May 13. The company reported a 37% decline in revenue and a net loss of €32.1 million, compared to €9.2 million a year earlier. Concurrently, the group unveiled a reorganization plan aimed at reducing its operational expenses by 25 to 35% and its global workforce by 10 to 15%. During this announcement, Valneva adjusted its 2026 revenue forecast to between €135 and €150 million, citing a decline in third-party product sales and unfavorable trends in travel vaccines. The capital context remains challenging: the biotech completed a reserved offer of €84 million at the end of April, with €37 million at closing and up to €47 million contingent on the exercise of warrants.
The Stock is 1.32% Below its 20-Day Moving Average and Close to the €2.26 Support
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock is below its 20-day moving average (€2.43), and the gap widens with longer averages: the 50-day MA is 20.86% above the current price, the 200-day MA more than 37% above. This configuration indicates a bearish trend that has been established for several months. The RSI at 41 remains in the neutral zone, with no pronounced oversold signal despite the accumulated decline. The €2.26 support, already tested at the beginning of May, is now less than 6% from the current price. The next important event is scheduled for May 21 with the company's participation in the Bernstein European Small & Mid-Cap Conference. The general meeting will be held on June 25, and the semi-annual results for 2026 are expected on August 13.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
